Explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics
• Offers non-technical summaries of the most recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD, and ayahuasca
• Includes the work of Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker
Embracing the revival of psychedelic research and the discovery of new therapeutic uses, clinical psychologist Dr. Richard Louis Miller discusses what is happening today in psychedelic medicine--and what will happen in the future--with top researchers and thinkers in this field, including Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker.
Dr. Miller and his contributors explore the biochemistry of consciousness and the use of psychedelics for self-discovery and healing. They discuss the use of psilocybin for releasing fear in the terminally ill and the potential for MDMA-assisted psychotherapy in the treatment of PTSD. They examine Dr. Charles Grob’s research on the indigenous use and therapeutic properties of ayahuasca and Dr. Gabor Mate’s attempt to transport this plant medicine to a clinical setting with the help of Canada’s Department of National Health.
Dr. Miller and his contributors explore the ongoing efforts to restore psychedelic therapies to the health field. They also discuss the newly shifting political climate and the push for new research, offering hope for an end to the War on Drugs and a potential renaissance of research into psychedelic medicines around the world.
Inhaltsverzeichnis
About the Author < BR> < BR> INTRODUCTION < BR> What’ s Happening in America? < BR> < BR> ONE < BR> LSD: A Powerful Tool < BR> < BR> The Biochemistry of Changes in Consciousness < BR> David Nichols, PhD < BR> < BR> LSD Brain-Imaging Studies< BR> Amanda Feilding < BR> < BR> Observations from 4, 000 LSD Sessions < BR> Stanislav Grof, MD, PhD < BR> < BR> The Condensed Psychedelic Explorer’ s Guide < BR> James Fadiman, PhD < BR> < BR> TWO < BR> MDMA: Heart Medicine < BR> Drawing a Map from “ X” to Rx < BR> Rick Doblin, PhD < BR> < BR> Pioneering Government-Approved Research < BR> Charles Grob, MD < BR> < BR> Demonstrating MDMA’ s Safety and Efficacy in Treating End-of-Life Anxiety < BR> Phil Wolfson, MD < BR> < BR> MDMA for Post-traumatic Stress Disorder < BR> Michael Mithoefer, MD, and Annie Mithoefer, BSN < BR> < BR> THREE < BR> Psilocybin < BR> < BR> Spiritual Psychopharmacology < BR> Roland Griffiths, PhD, and Katherine MacLean, PhD < BR> < BR> Seeking Solace for the Terminally Ill < BR> Charles Grob, MD < BR> < BR> Psilocybin and Depression < BR> Amanda Feilding < BR> < BR> FOUR < BR> Ayahuasca: Teacher Plant < BR> < BR> Hard Science in the Amazon < BR> Charles Grob, MD < BR> < BR> Plants Meet People < BR> Dennis McKenna, PhD < BR> < BR> The Science of the Sacred < BR> Rick Doblin, PhD < BR> < BR> FIVE < BR> Psychiatric Prescription Drugs: Tired Soldiers < BR> < BR> Questioning the Psychiatric Paradigm < BR> Robert Whitaker < BR> < BR> Resisting the “ New Normal” of Overmedication < BR> Julie Holland, MD < BR> < BR> EPILOGUE < BR> FDA Approval by 2021? < BR> < BR> An Optimistic Forecast< BR> Rick Doblin, PhD < BR> < BR> Acknowledgments < BR> < BR> Index